Last reviewed · How we verify

NCT06674226

Effects of Ciprofol on Postoperative Delirium and Outcomes in Elderly Patients Undergoing Major Thoracic Surgery

Recruiting now Phase 4 Last updated 17 November 2025
What this trial tests

Phase 4 trial testing Ciprofol in Postoperative Delirium (POD) in 214 participants. Currently enrolling.

Timeline
23 December 2024
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorWang Tianlong
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment214
Start date23 December 2024
Primary completion30 June 2026
Estimated completion30 June 2026
Sites9 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Wang Tianlong

Who can join

65 and older, any sex, with Postoperative Delirium (POD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are many factors that make elderly patients prone to POD. On the basis of these factors, surgery and anesthesia can increase the incidence of POD in elderly patients. Deep depth of intraoperative anesthesia and persistent hypotension may increase the risk of POD occurrence in elderly patients. So far, no specific POD prevention method has been found. In recent years, a large number of studies on POD have brought forward more new views on its pathogenesis, prevention and treatment. There is insufficient evidence to recommend specific anesthetic agents and dosages to reduce the risk of POD in elderly patients, and only low-quality evidence to recommend propofol. At present, it is considered that the best way to reduce postoperative delirium is perioperative risk management, to evaluate high-risk patients or patients undergoing high-risk surgery as extensive as possible, and to quantify their risk of postoperative delirium. Effective measures include depth management of anesthesia, multi-modal analgesia management, and optimization of drug intervention. Ciprofol is a class 1 innovative drug independently developed by China and with global independent intellectual property rights. Ciprofol has been widely used in anesthesiology and critical care medicine. The pre-market phase I-III and post-market data showed that during the induction and maintenance of general anesthesia, Ciprofol had less impact on hemodynamics and more stable anesthesia depth than propofol. Relevant studies have shown that Ciprofol can reduce the risk of hypotension, and can provide better brain oxygenation and more stable intraoperative hemodynamics than propofol. At present, the influence of different sedative drugs on POD incidence in elderly patients remains to be studied. Therefore, we will apply Ciprofol or propofol in elderly patients undergoing thoracic surgery to observe their influence on POD incidence and provide reference for clinical use.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of ciprofol on postoperative delirium and outcomes in older patients undergoing major thoracic surgery: protocol for a multicentre, prospective, single-blinded, randomised controlled study.
    Hong P, Liu Q, Ouyang W, Luo A, et al · · 2025 · cited 1× · PMID 40829819 · DOI 10.1136/bmjopen-2025-105818

Verify or expand the search:

Other trials of Ciprofol

Trials testing the same drug.

Other recruiting trials for Postoperative Delirium (POD)

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06674226.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing